Results 261 to 270 of about 346,610 (333)

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Risk factor and operation influence of intracranial hemorrhage following ventriculoperitoneal shunt. [PDF]

Sci Rep
Wang W, Lin J, Guo X, Gao S, Zhu J, Hong Y.   +5 more
europepmc   +1 more source

Mid‐term survival in patients awaiting heart and kidney transplantation with Impella 5.5 support

ESC Heart Failure, EarlyView.
Abstract Background Patients with end‐stage heart failure and chronic kidney disease requiring dual‐organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi‐organ failure.
Smruti Desai, Smit Paghdar, Jose Ruiz, Ji‐Min Jang, Sharan Malkani, Daniel S. Yip, Juan Leoni, Jose Nativi, Basar Sareyyupoglu, Kevin Landolfo, Si Pham, Parag Patel, Rohan Goswami   +12 more
wiley   +1 more source

Substantial loss of T cells upon lymphocyte isolation from heparin-anticoagulated peripheral blood. [PDF]

Front Immunol
Berg V, Ross JA, Dampmann M, Küppers R, Budeus B.   +4 more
europepmc   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices

ESC Heart Failure, EarlyView.
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim, Hoang Nhat, Mahmoud Abdelnabi, Beani Forst, Mohamed Allam, Xuan Ci Mee, Ghee Kheng Lim, George Bcharah, Timothy Barry, Juan Farina, Chadi Ayoub, Reza Arsanjani, Kwan Lee   +12 more
wiley   +1 more source

First-Ever Stroke Outcomes in Patients with Atrial Fibrillation: A Retrospective Cross-Sectional Study. [PDF]

Medicines (Basel)
Maduna I, Vidaković D, Črnac P, Saleh C, Budinčević H.   +4 more
europepmc   +1 more source

Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis [PDF]

, 2017
Blinder, M., Derfler, M. C, Duncan, J. R, et al,, Lewis, L., Nieters, P., Washington University School of Medicine in St. Louis, Saad, N., Vedantham, S.   +7 more
core   +1 more source

Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58

ESC Heart Failure, EarlyView.
Abstract Background Galectin‐3 (Gal‐3) is a circulating biomarker of fibrosis, with higher levels being associated with an increased risk of progression of heart failure and kidney disease. Patients with type 2 diabetes mellitus (T2DM) are at increased risk of both.
Paul M. Haller, Stephen D. Wiviott, David D. Berg, Petr Jarolim, Erica L. Goodrich, Deepak L. Bhatt, Ingrid Gause‐Nilsson, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Itamar Raz, Marc S. Sabatine, David A. Morrow   +12 more
wiley   +1 more source

Eco-benign spectrofluorimetric analysis of icariin in a nano-formulation using green quantum dots: insights from <i>in vitro</i> anticoagulant and docking studies. [PDF]

RSC Adv
Elbordiny HS, Ahmed AR, Elnaggar MM, Agwa MM, Ragab MA, Aboras SI.   +5 more
europepmc   +1 more source

Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF‐ImmunoCS

ESC Heart Failure, EarlyView.
Abstract Aims We have previously shown that patients who develop heart‐reactive antibodies (HRAs) de novo after a heart failure (HF) hospitalization are at increased risk of adverse outcomes, lending weight to the hypothesis that B cells may play a pivotal role in HF progression.
Niklas Beyersdorf, Boshra Afshar, Dora Pelin, Maximilian Bauser, Elisa Kaiser, Janna Lamers, Jannika Pätkau, Mairin Heil, Dennis Göpfert, Hanna Hepp, Wafaa Al Hassan, Thomas Kerkau, Fabian Kerwagen, Roland Jahns, Valerie Boivin‐Jahns, Stefan Frantz, Gustavo Ramos, Ulrich Hofmann, Stefan Störk, Caroline Morbach   +19 more
wiley   +1 more source